LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that results from ongoing Phase I and Phase II clinical trials of Cougar’s investigational drug, CB7630 (abiraterone acetate), were presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is currently taking place in Chicago. The data was presented today in four separate oral presentations. These presentations are further detailed below:
